ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 815

The Novel Anti-BICD2 Autoantibody Potentially Predicts a Favorable Disease Course in SSc

Johannes Schulte-Pelkum1, Daniel Wirtz1, Petra Budde1, Hans-Dieter Zucht1, Peter Schulz-Knappe1, Prof. Dr. Matthias Schneider2, Suzana Jordan3, Oliver Distler3, Britta Maurer3 and Nicolas Hunzelmann4, 1Protagen AG, Dortmund, Germany, 2Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, 3Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 4Department of Dermatology, University of Cologne, Cologne, Germany

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: autoantibodies, autoantigens, Biomarkers and systemic sclerosis, Diagnostic Tests

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: To evaluate clinical associations of our recently discovered systemic sclerosis-specific auto-antigen BICD2 in clinically well characterized systemic sclerosis (SSc) cohorts from two tertiary referral centers.

Methods: Serum samples were obtained from the biobanks of the Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, and Department of Dermatology, University of Cologne, Cologne. The analysis included samples collected from patients suffering from SSc (n=302) systemic lupus erythematosus (n=39), Sjogren’s syndrome (n=11), rheumatoid arthritis (n=20), myositis (n=20) and healthy volunteers (n=99). Clinical annotation data, including age, gender, disease duration, MRSS, detailed information on organ involvement making up to a total of either >50 or >100 clinical data points (depending on the site) was available for more than 80% of all SSc serum samples included in this study. All samples were analyzed on the novel Multilisa BICD2 (CE), an ELISA for the semi-quantitative detection of anti-BICD2 antibodies in human serum or plasma.

Results: We found anti-BICD2 with a prevalence of 28% and 32% in the groups of SSc patients of the respective cohort, and only in 4.2% in cohorts with other rheumatic diseases or healthy controls (OR=8.702). Anti-BICD2 autoantibodies were present in a subgroup of SSc patients where skin fibrosis was either from the limited cutaneous subtype (p=0.0002) or restricted to sclerodactyly (p=0.0037). Within this line, anti-BICD2 autoantibodies showed a significantly higher titer in patients with moderate skin involvement reflected by low MRSS-stages (p=0.001). Analysis of pulmonary involvement revealed elevated anti-BICD2 titers in the group of patients not suffering from lung fibrosis measured by high resolution computer tomography (HCRT) (p=0.0001). Of note, the highest a-BICD2 values were observed in the group of patients having a residual transfer capability of 61-80% (DLCO stage 1 of 4). Anti-BICD2 autoantibodies were also found to be more prominent in the group of patients having a disease duration of more than 3 years.

Conclusion: In this study, we were able to further confirm the diagnostic value and high specificity of the newly discovered BICD2 autoantigen. Anti-BICD2 autoantibodies were found to be elevated in patients suffering from limited SSc, and anti-BICD2 reactivity was found to be related to clinical observations of a moderate course of disease.


Disclosure: J. Schulte-Pelkum, Protagen AG, 3; D. Wirtz, Protagen AG, 3; P. Budde, Protagen AG, 3; H. D. Zucht, Protagen AG, 3; P. Schulz-Knappe, Protagen AG, 3; P. D. M. Schneider, Protagen AG, 5; S. Jordan, None; O. Distler, None; B. Maurer, AbbVie, Protagen, EMDO, 2, 9,Roche, Actelion, 9; N. Hunzelmann, None.

To cite this abstract in AMA style:

Schulte-Pelkum J, Wirtz D, Budde P, Zucht HD, Schulz-Knappe P, Schneider PDM, Jordan S, Distler O, Maurer B, Hunzelmann N. The Novel Anti-BICD2 Autoantibody Potentially Predicts a Favorable Disease Course in SSc [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-novel-anti-bicd2-autoantibody-potentially-predicts-a-favorable-disease-course-in-ssc/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-novel-anti-bicd2-autoantibody-potentially-predicts-a-favorable-disease-course-in-ssc/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology